Literature DB >> 21254231

Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?

Douglas C Bauer1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21254231     DOI: 10.1002/jbmr.335

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


× No keyword cloud information.
  7 in total

1.  Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures.

Authors:  T Lehmann; D Aeberli
Journal:  Osteoporos Int       Date:  2017-06-06       Impact factor: 4.507

Review 2.  Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.

Authors:  Aline G Costa; Natalie E Cusano; Barbara C Silva; Serge Cremers; John P Bilezikian
Journal:  Nat Rev Rheumatol       Date:  2011-06-14       Impact factor: 20.543

3.  Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.

Authors:  Le T Duong
Journal:  Bonekey Rep       Date:  2012-05-02

Review 4.  For whom the bell tolls: distress signals from long-lived osteocytes and the pathogenesis of metabolic bone diseases.

Authors:  Stavros C Manolagas; A Michael Parfitt
Journal:  Bone       Date:  2012-09-23       Impact factor: 4.398

Review 5.  [Cathepsin K antagonists: preclinical and clinical data].

Authors:  Marion Gamsjäger; Heinrich Resch
Journal:  Wien Med Wochenschr       Date:  2015-01-09

Review 6.  Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib.

Authors:  Natalie A Sims; Kong Wah Ng
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

Review 7.  Potential role of odanacatib in the treatment of osteoporosis.

Authors:  Kong Wah Ng
Journal:  Clin Interv Aging       Date:  2012-07-12       Impact factor: 4.458

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.